COMMUNIQUÉS West-GlobeNewswire

Spectral AI Achieves 100% Pediatric Enrollment in Burn Centers for Pivotal U.S. Burn Study
02/07/2024
DALLAS, July 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
01/07/2024
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency virus (HIV) HOOKIPA [...]
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01/07/2024
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Goodness Growth Holdings Announces Name Change to Vireo Growth Inc.
01/07/2024
– Subordinate voting shares expected to begin trading under new ticker symbols on July 8, 2024 – –Ticker symbol “VREO” on the CSE in Canada (CSE: VREO); “VREOF” on OTCQX Market (OTCQX: VREOF) – MINNEAPOLIS, July 01, [...]
Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets
01/07/2024
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for [...]
AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary
01/07/2024
Donna Shiroma retires after distinguished service as General Counsel VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company [...]
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
01/07/2024
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
01/07/2024
LAUSANNE, Switzerland, July 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 172,400 of the Company’s common shares to [...]
Stryker to announce financial results for its second quarter of fiscal year 2024
01/07/2024
Portage, Michigan, July 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for first quarter of fiscal year 2024 on Tuesday, July 30, 2024. A press release will be issued at [...]
Nexalin Technology Announces Closing of $5.2 Million Public Offering
01/07/2024
HOUSTON, TX, July 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the closing of its previously announced public offering of 3,000,000 shares of [...]
A-S Medication Solutions Announces Strategic Transition
01/07/2024
LIBERTYVILLE, Ill., July 01, 2024 (GLOBE NEWSWIRE) -- A-S Medication Solutions (ASM) today announced a strategic transition of its relationship with Triple Aim Consulting, LLC (“TAC”). For a number of years, ASM has had [...]
BioPorto confirms market acceptance of NGAL products with US standing order.
01/07/2024
July 1, 2024 News Release BioPorto confirms market acceptance of NGAL products with US standing order. COPENHAGEN, Denmark and BOSTON, MA, USA, July 1, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH: [...]
Protect Pharmaceutical Corp. Issues Corporate Update
01/07/2024
ANKARA, Turkey, July 01, 2024 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp.'s (OTC: PRTT) (“Company”) President, Ali Yildiz, provides its shareholders with the following informational update: "July 1, 2024 Dear [...]
Le CHMP émet un avis favorable pour BALVERSA® (erdafitinib) dans le traitement des patients adultes atteints d’un carcinome urothélial non résécable ou métastatique présentant des altérations génétiques sensibles du FGFR3
01/07/2024
En cas d’approbation, l’erdafitinib deviendrait le premier traitement ciblant les altérations du FGFR3 chez les patients atteints de carcinome urothélial métastatique, l’un des cancers les plus répandus en Europe 1 La [...]
Novo Nordisk A/S - share repurchase programme
01/07/2024
Bagsværd, Denmark, 01 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Merit Medical Announces Asset Purchase Agreement with EndoGastric Solutions, Inc.®
01/07/2024
Asset acquisition expands Merit’s endoscopy portfolio with a minimally invasive solution for patients suffering from chronic gastroesophageal reflux disease (GERD). Asset acquisition projected to add approximately $30 [...]
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024
01/07/2024
ZTlido ® net sales for the month of June 2024 grew in the range of 70% to 104%, compared to the same period last year. ZTlido ® net sales for the quarter ended June 2024 grew in the range of 28% to 42%, compared to the [...]
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
01/07/2024
The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint of 11% Company [...]
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium
01/07/2024
SOLANA BEACH, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]

Pages